{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:20:18Z","timestamp":1792693218250,"version":"4.5.0"},"reference-count":67,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Pediatric migraine substantially impacts quality of life and academic performance among children and adolescents. Understanding the efficacy and safety of pharmacological interventions for migraine prophylaxis in this population is crucial for developing effective treatment strategies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To conduct a comprehensive network meta-analysis to evaluate the efficacy and safety associated with pharmacological treatments for pediatric migraine prophylaxis among pediatric patients with a migraine diagnosis and assess interventions involving various oral pharmacological interventions compared with each other and placebo.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, Embase, and SCOPUS were searched for publications up to September 2023. Search terms and indexing were chosen to encompass relevant studies, focusing on randomized clinical trials in pediatric migraine prophylaxis.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Inclusion criteria targeted randomized clinical trials involving pediatric patients with migraine. Studies were selected based on their examination of oral pharmacological interventions. The search yielded an initial 9162 citations.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Data extraction adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. Five investigators independently extracted study data into a spreadsheet in duplicate. Study-level estimates were calculated, employing a random-effects model for primary and secondary outcomes due to identified heterogeneity. Data analysis was conducted from December 2023 to March 2024<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was migraine frequency (number of attacks per month). Secondary outcomes included a 50% or greater responder rate, headache duration, headache intensity, and disability (assessed by pediatrics migraine-specific disability tool). Adverse events were also evaluated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The analysis incorporated 45 trials with 3771 participants. Compared with placebo, pregabalin (ratio of means [RoM], 0.38; 95% CI, 0.18-0.79) and topiramate with vitamin D3 (RoM, 0.44; 95% CI, 0.30-0.65) were associated with reduction in migraine frequency. Flunarizine (RoM, 0.46; 95% CI, 0.26-0.81), levetiracetam (RoM, 0.47; 95% CI, 0.30-0.72), riboflavin (RoM, 0.50; 95% CI, 0.32-0.77), cinnarizine (RoM, 0.64; 95% CI, 0.46-0.88), topiramate (RoM, 0.70; 95% CI, 0.55-0.89), and amitriptyline (RoM, 0.73; 95% CI, 0.54-0.97) were also associated with reduction in migraine frequency, but these findings were drawn from individual studies. For the 50% or greater responder rate, flunarizine and \u03b1-lipoic acid (risk ratio [RR], 8.73; 95% CI, 2.44-31.20), flunarizine (RR, 4.00; 95% CI, 1.38-11.55), pregabalin (RR, 1.88; 95% CI, 1.13-3.14), and cinnarizine (RR, 1.46; 95% CI, 1.04-2.05) were associated with significantly greater effectiveness than placebo. Compared with placebo, propranolol and cinnarizine (RoM, 0.45; 95% CI, 0.28-0.72), pregabalin (RoM, 0.57; 95% CI, 0.33-0.96), valproate (RoM, 0.60; 95% CI, 0.49-0.72), levetiracetam (RoM, 0.62; 95% CI, 0.50-0.77), and cinnarizine (RoM, 0.64; 95% CI, 0.54-0.76) were significantly associated with reduction in headache intensity. However, no treatments were associated with significant improvements in quality of life or reduction of the duration of migraine attacks. Adverse events were higher with amitriptyline (RR, 3.81; 95% CI, 1.41-10.32), topiramate (RR, 4.34; 95% CI, 1.60-11.75), and valproate (RR, 5.93; 95% CI, 1.93-18.23) compared with placebo.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this network meta-analysis of randomized clinical trials, topiramate and pregabalin were associated with reduction in headache frequency and intensity. Although there were also other drugs that showed statistically significant results (flunarizine, riboflavin, amitriptyline, and cinnarizine), more studies were required for a robust conclusion. None of the drugs were associated with improved quality of life or attack duration, underscoring the need for further research to develop more comprehensive treatment strategies and explore the potential of combination therapies, especially those involving vitamins. Future studies should focus on validating these findings and expanding the treatment landscape for pediatric migraine management.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.38666","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:05:02Z","timestamp":1728558302000},"page":"e2438666","source":"Crossref","is-referenced-by-count":21,"title":["Preventive Medications in Pediatric Migraine"],"prefix":"10.1001","volume":"7","author":[{"given":"Omid","family":"Kohandel Gargari","sequence":"first","affiliation":[{"name":"Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"School of Medicine, Alborz University of Medical Sciences, Karaj, Iran"},{"name":"Neuroscience Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoureh","family":"Togha","sequence":"additional","affiliation":[{"name":"Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Headache Department, Neurology Ward, Sina University Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Mohammadifard","sequence":"additional","affiliation":[{"name":"School of Medicine, Alborz University of Medical Sciences, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Abyaneh","sequence":"additional","affiliation":[{"name":"School of Medicine, Alborz University of Medical Sciences, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Mobader Sani","sequence":"additional","affiliation":[{"name":"Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"NeuroWeb Association, Students\u2019 Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Samiee","sequence":"additional","affiliation":[{"name":"Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"NeuroWeb Association, Students\u2019 Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Kermanpour","sequence":"additional","affiliation":[{"name":"Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Seighali","sequence":"additional","affiliation":[{"name":"School of Medicine, Alborz University of Medical Sciences, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraidoon","family":"Haghdoost","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"1","key":"zoi241121r1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s10194-023-01541-0","article-title":"Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis.","volume":"24","author":"Onofri","year":"2023","journal-title":"J Headache Pain"},{"issue":"12","key":"zoi241121r2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1469-8749.2010.03793.x","article-title":"Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies.","volume":"52","author":"Abu-Arafeh","year":"2010","journal-title":"Dev Med Child Neurol"},{"issue":"18","key":"zoi241121r3","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1212\/WNL.0b013e318271f812","article-title":"Migraine and migraine subtypes in preadolescent children: association with school performance.","volume":"79","author":"Arruda","year":"2012","journal-title":"Neurology"},{"issue":"12","key":"zoi241121r4","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/jamapediatrics.2022.3940","article-title":"Anxiety and depressive symptoms and disorders in children and adolescents with migraine: a systematic review and meta-analysis.","volume":"176","author":"Falla","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"1","key":"zoi241121r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the international headache society (IHS) the international classification of headache disorders.","volume":"38","author":"Arnold","year":"2018","journal-title":"Cephalalgia"},{"issue":"3","key":"zoi241121r6","first-page":"382","article-title":"Off-label prescribing for children with migraines in US ambulatory care settings.","volume":"23","author":"Lai","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"zoi241121r7","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.3928\/19382359-20180129-02","article-title":"Management of pediatric migraine: current therapies.","volume":"47","author":"Khrizman","year":"2018","journal-title":"Pediatr Ann"},{"issue":"4","key":"zoi241121r8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005220.pub2","article-title":"Drugs for the acute treatment of migraine in children and adolescents.","volume":"4","author":"Richer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"zoi241121r9","doi-asserted-by":"publisher","first-page":"e1411","DOI":"10.1542\/peds.2011-2455","article-title":"Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine.","volume":"129","author":"Derosier","year":"2012","journal-title":"Pediatrics"},{"issue":"11","key":"zoi241121r10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1212\/WNL.0000000000008095","article-title":"Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society.","volume":"93","author":"Oskoui","year":"2019","journal-title":"Neurology"},{"key":"zoi241121r11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/PHMT.S334744","article-title":"Management of chronic migraine in children and adolescents: where are we in 2022?","volume":"13","author":"Gibler","year":"2022","journal-title":"Pediatric Health Med Ther"},{"issue":"7","key":"zoi241121r12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamaneurol.2018.0046","article-title":"The changing landscape of pediatric migraine therapy: a review.","volume":"75","author":"Patterson-Gentile","year":"2018","journal-title":"JAMA Neurol"},{"issue":"7","key":"zoi241121r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"10","key":"zoi241121r14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"71","key":"zoi241121r15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"zoi241121r16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamapediatrics.2019.5856","article-title":"Efficacy, safety, and acceptability of pharmacologic treatments for pediatric migraine prophylaxis: a systematic review and network meta-analysis.","volume":"174","author":"Locher","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"9","key":"zoi241121r17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The International Classification of Headache Disorders, 3rd edition (beta version).","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","journal-title":"Cephalalgia"},{"issue":"11","key":"zoi241121r18","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1212\/WNL.57.11.2034","article-title":"PedMIDAS: development of a questionnaire to assess disability of migraines in children.","volume":"57","author":"Hershey","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"zoi241121r20","first-page":"77","article-title":"L-carnitine versus Propranolol for pediatric migraine prophylaxis.","volume":"15","author":"Amini","year":"2021","journal-title":"Iran J Child Neurol"},{"issue":"7","key":"zoi241121r21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/j.1526-4610.2008.01081.x","article-title":"Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study.","volume":"48","author":"Apostol","year":"2008","journal-title":"Headache"},{"issue":"4","key":"zoi241121r22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.pediatrneurol.2014.05.031","article-title":"Efficacy and safety of cinnarizine in the prophylaxis of migraine in children: a double-blind placebo-controlled randomized trial.","volume":"51","author":"Ashrafi","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"4","key":"zoi241121r23","first-page":"18","article-title":"Cinnarizine versus topiramate in prophylaxis of migraines among children and adolescents: a randomized, double-blind clinical trial.","volume":"8","author":"Ashrafi","year":"2014","journal-title":"Iran J Child Neurol"},{"issue":"5","key":"zoi241121r24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejpn.2005.05.004","article-title":"Sodium valproate versus propranolol in paediatric migraine prophylaxis.","volume":"9","author":"Ashrafi","year":"2005","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"zoi241121r25","first-page":"276","article-title":"Comparison of propranolol and pregabalin for prophylaxis of childhood migraine: a randomised controlled trial.","volume":"53","author":"Bakhshandeh Bali","year":"2015","journal-title":"Acta Med Iran"},{"issue":"1","key":"zoi241121r26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1526-4610.1993.hed3301036.x","article-title":"A placebo-controlled crossover trial using trazodone in pediatric migraine.","volume":"33","author":"Battistella","year":"1993","journal-title":"Headache"},{"issue":"5","key":"zoi241121r27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1526-4610.1990.hed3005264.x","article-title":"A placebo-controlled crossover trial of nimodipine in pediatric migraine.","volume":"30","author":"Battistella","year":"1990","journal-title":"Headache"},{"issue":"4","key":"zoi241121r28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/11316270-000000000-00000","article-title":"A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients.","volume":"12","author":"Bidabadi","year":"2010","journal-title":"Paediatr Drugs"},{"issue":"12","key":"zoi241121r29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1177\/0333102410365106","article-title":"Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial.","volume":"30","author":"Bruijn","year":"2010","journal-title":"Cephalalgia"},{"issue":"10-11","key":"zoi241121r30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/08830738221092882","article-title":"The impact of vitamin D3 supplementation to topiramate therapy on pediatric migraine prophylaxis.","volume":"37","author":"Kotb Elmala","year":"2022","journal-title":"J Child Neurol"},{"issue":"4","key":"zoi241121r31","first-page":"77","article-title":"Efficacy of topiramate alone and topiramate plus vitamin d3 in the prophylaxis of pediatric migraine: a randomized clinical trial.","volume":"14","author":"Fallah","year":"2020","journal-title":"Iran J Child Neurol"},{"issue":"1","key":"zoi241121r32","first-page":"47","article-title":"A randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children.","volume":"12","author":"Fallah","year":"2018","journal-title":"Iran J Child Neurol"},{"issue":"11","key":"zoi241121r33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12098-013-0976-0","article-title":"Topiramate and propranolol for prophylaxis of migraine.","volume":"80","author":"Fallah","year":"2013","journal-title":"Indian J Pediatr"},{"issue":"4","key":"zoi241121r34","first-page":"55","article-title":"Administration in efficacy of melatonin reducing headaches in children with migraines and sleep disorders: a randomized clinical trial study.","volume":"16","author":"Fayyazi","year":"2022","journal-title":"Iran J Child Neurol"},{"issue":"1","key":"zoi241121r35","first-page":"9","article-title":"Omega 3 in childhood migraines: a double blind randomized clinical trial.","volume":"10","author":"Fayyazi","year":"2016","journal-title":"Iran J Child Neurol"},{"issue":"9","key":"zoi241121r36","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/head.14600","article-title":"Melatonin for migraine prevention in children and adolescents: a randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.","volume":"63","author":"Gelfand","year":"2023","journal-title":"Headache"},{"issue":"3","key":"zoi241121r37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5114\/polp.2019.86434","article-title":"The efficacy and safety of levetiracetam in the prophylaxis of migraine headaches in children - a randomised trial.","volume":"94","author":"Ghazavi","year":"2019","journal-title":"Pediatr Pol"},{"issue":"1","key":"zoi241121r38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000115983","article-title":"Pizotifen (sanomigran) in childhood migraine: a double-blind controlled trial.","volume":"25","author":"Gillies","year":"1986","journal-title":"Eur Neurol"},{"issue":"3","key":"zoi241121r39","first-page":"121","article-title":"Comparing pregabalin and sodium valproate in pediatric migraine prophylaxis: a randomized clinical trial.","volume":"17","author":"Jafari","year":"2023","journal-title":"Iran J Child Neurol"},{"issue":"9","key":"zoi241121r41","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s12098-022-04279-w","article-title":"Effect of propranolol prophylaxis on headache frequency in children with migraine without aura: a randomized, double-blind, placebo-controlled trial.","volume":"90","author":"Keerthana","year":"2023","journal-title":"Indian J Pediatr"},{"issue":"7","key":"zoi241121r42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1177\/0883073807304201","article-title":"Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial.","volume":"22","author":"Lakshmi","year":"2007","journal-title":"J Child Neurol"},{"issue":"3","key":"zoi241121r43","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1542\/peds.2008-0642","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age.","volume":"123","author":"Lewis","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"zoi241121r44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1600-0404.1974.tb01350.x","article-title":"Propranolol used in prophylaxis of migraine in children.","volume":"50","author":"Ludvigsson","year":"1974","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"zoi241121r45","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1177\/0883073808318053","article-title":"High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial.","volume":"23","author":"MacLennan","year":"2008","journal-title":"J Child Neurol"},{"issue":"12","key":"zoi241121r46","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1177\/0333102419851814","article-title":"Levetiracetam for prophylactic treatment of pediatric migraine: a randomized double-blind placebo-controlled trial.","volume":"39","author":"Montazerlotfelahi","year":"2019","journal-title":"Cephalalgia"},{"issue":"3","key":"zoi241121r47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejpain.2007.06.003","article-title":"Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study.","volume":"12","author":"Oelkers-Ax","year":"2008","journal-title":"Eur J Pain"},{"issue":"12","key":"zoi241121r48","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/jcph.2331","article-title":"Evaluation of safety and efficacy of add-on Alpha-lipoic acid on migraine prophylaxis in an adolescent population: a randomized controlled trial.","volume":"63","author":"Puliappadamb","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"zoi241121r49","first-page":"143","article-title":"The effects of vitamin b-complex supplementation on serum homocysteine levels and migraine severity in children: a randomized controlled trial.","volume":"17","author":"Sadeghvand","year":"2023","journal-title":"Iran J Child Neurol"},{"issue":"3","key":"zoi241121r50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1046\/j.1468-2982.1986.0603155.x","article-title":"L-5-hydroxytryptophan versus placebo in childhood migraine prophylaxis: a double-blind crossover study.","volume":"6","author":"Santucci","year":"1986","journal-title":"Cephalalgia"},{"issue":"8","key":"zoi241121r51","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3109\/00207454.2013.776048","article-title":"A randomized trial comparing amitriptyline versus topiramate for the prophylaxis of chronic daily headache in pediatric patients.","volume":"123","author":"Sezer","year":"2013","journal-title":"Int J Neurosci"},{"issue":"8","key":"zoi241121r53","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1177\/0333102411406755","article-title":"A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine.","volume":"31","author":"Slater","year":"2011","journal-title":"Cephalalgia"},{"key":"zoi241121r54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/03331024850050S227","article-title":"Flunarizine v. placebo in childhood migraine: a double-blind study.","volume":"5","author":"Sorge","year":"1985","journal-title":"Cephalalgia"},{"issue":"2","key":"zoi241121r55","doi-asserted-by":"publisher","first-page":"6279","DOI":"10.19082\/6279","article-title":"Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial.","volume":"10","author":"Talebian","year":"2018","journal-title":"Electron Physician"},{"issue":"1","key":"zoi241121r56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13760-012-0011-7","article-title":"Efficacy and safety of cinnarizine in the prophylaxis of migraine headaches in children: an open, randomized comparative trial with propranolol.","volume":"112","author":"Togha","year":"2012","journal-title":"Acta Neurol Belg"},{"issue":"1","key":"zoi241121r57","first-page":"9","article-title":"Prophylaxis of childhood migraine: topiramate versus propranolol.","volume":"7","author":"Tonekaboni","year":"2013","journal-title":"Iran J Child Neurol"},{"issue":"10","key":"zoi241121r58","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1526-4610.2005.00262.x","article-title":"Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.","volume":"45","author":"Winner","year":"2005","journal-title":"Headache"},{"key":"zoi241121r60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/abr.abr_235_20","article-title":"A comparative study on the efficacy of coenzyme Q10 and amitriptyline in the prophylactic treatment of migraine headaches in children: a randomized controlled trial.","volume":"11","author":"Yaghini","year":"2022","journal-title":"Adv Biomed Res"},{"issue":"7","key":"zoi241121r61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1177\/0333102419888485","article-title":"Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: a randomized double-blind placebo-controlled trial.","volume":"40","author":"Amanat","year":"2020","journal-title":"Cephalalgia"},{"issue":"6","key":"zoi241121r62","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/archdischild-2017-312734","article-title":"Amitriptyline and topiramate are no better than placebo for childhood migraine.","volume":"102","author":"Dalrymple","year":"2017","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"6","key":"zoi241121r63","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/head.14474","article-title":"Impact of preventive pill-based treatment on migraine days: a secondary outcome study of the childhood and adolescent migraine prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments.","volume":"63","author":"Gibler","year":"2023","journal-title":"Headache"},{"issue":"2","key":"zoi241121r64","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa1610384","article-title":"Trial of amitriptyline, topiramate, and placebo for pediatric migraine.","volume":"376","author":"Powers","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi241121r65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"issue":"3","key":"zoi241121r66","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/bmjebm-2021-111906","article-title":"Component network meta-analysis in a nutshell.","volume":"28","author":"Tsokani","year":"2023","journal-title":"BMJ Evid Based Med"},{"issue":"3","key":"zoi241121r67","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamapediatrics.2013.508","article-title":"Pharmacologic treatment of pediatric headaches: a meta-analysis.","volume":"167","author":"El-Chammas","year":"2013","journal-title":"JAMA Pediatr"},{"key":"zoi241121r19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"zoi241121r40","unstructured":"Katibeh? P, Shirazi? RB, Shiraly? R. Comparing the efficacy of propranolol+ cinarizine and propranolol+placebo in controlling pediatric migraine headaches: A randomized controlled trial.? J Mazandaran Univ Med Sci. 2021;31(192):44-53."},{"key":"zoi241121r52","unstructured":"Shahnawaz? K, Mughal? BB, Madni? B, Malhi? KA, Siddiqui? MA. Comparison of efficacy and tolerability of melatonin and amitriptyline in children suffering with migraine.? Med Forum Monthly. 2019;30(5):12-15."},{"key":"zoi241121r59","unstructured":"Yadav? R, Singh? TP, Shukla? SK. Sodium valproate versus topiramate for prophylaxis of migraine among children and adolescents: a randomised trial.? Indian Acad of Clinical Med. 2017;18(3):180-183."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824677\/kohandel_gargari_2024_oi_241121_1727811818.96597.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:05:13Z","timestamp":1728558313000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824677"}},"subtitle":["A Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.38666","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}